What Degra Treats: Therapeutic Uses and Symptom Support

This medicine is commonly used to help manage two distinct primary therapeutic domains: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

Symptom Relief and Therapeutic Support

In clinical settings, the medication is generally relevant for addressing symptoms that create noticeable physiological strain and interfere with daily functioning. Specifically, it is applied across conditions presenting with disruptive manifestations and for managing the significant symptomatic burden.

This offers symptomatic relief that helps patients cope more steadily with difficult episodes and provides supportive relief when symptoms interfere with routine activities. It may assist with maintaining functional stability in the targeted areas.

“The medication is commonly used when short-term symptomatic assistance is needed to address periods of heightened physiological stress.”

---

Quick Fact: Relief for Functional Strain This medicine is applied to ease challenging symptoms associated with physical discomfort and systemic imbalance, and it supports the patient during difficult episodes by helping ease distress.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Degra?

The eligibility for Degra (sildenafil) is strictly defined by regulatory health authorities and centers around contraindications, age, and pre-existing health status.

---

Absolute Non-Eligibility (Contraindications)

Degra is formally prohibited for use in patients taking any form of organic nitrates or the guanylate cyclase stimulator riociguat, due to the risk of severe, life-threatening hypotension.

Use is also contraindicated in patients with a known hypersensitivity to sildenafil, a recent history of stroke or myocardial infarction, severe hepatic impairment (Child-Pugh Class C), or specific eye conditions like Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) or retinitis pigmentosa [NIH, EMA, FDA].

---

Age and Conditional Eligibility

• Adults (18+): Generally eligible for the approved indications.
• Pediatric Patients: Only eligible for the Pulmonary Arterial Hypertension (PAH) indication, starting at 1 year of age. Use is not recommended for infants under 1 year.
• Geriatric Patients (65+): Considered eligible, but dose consideration is recommended for the Erectile Dysfunction (ED) indication due to reduced drug clearance.

---

Organ Impairment and Restrictions

Patients with severe renal impairment ( Creatinine Clearance < 30 mL/min) or hepatic impairment require conditional use, as the official label recommends consideration of a lower starting dose. Caution is also advised for patients with anatomical penile deformation or conditions predisposing to prolonged erection (priapism), such as sickle cell anemia [EMA, FDA].

Degra Interactions with other medicines and products

Degra (sildenafil) has officially documented interaction profiles, primarily involving additive blood pressure lowering effects and altered drug clearance. All interaction statements are derived from government regulatory documents.

---

Contraindicated Combinations

Co-administration is contraindicated with the following drug classes due to the risk of severe, potentially life-threatening hypotension from a potentiated vasodilatory effect:

• Nitrates and Nitric Oxide Donors: All forms of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate) or nitric oxide donors are prohibited.
• Guanylate Cyclase (sGC) Stimulators: Co-administration with Riociguat is contraindicated.

---

Pharmacokinetic and Exposure Interactions

Sildenafil is mainly metabolized by Cytochrome P450 (CYP) isoenzymes CYP3A4 (major route) and CYP2C9 (minor route). Inhibitors of these enzymes increase sildenafil exposure ( AUC, C max).

Interaction Type	Interacting Substance/Class	Official Regulatory Status
Strong CYP3A4 Inhibition	Ritonavir	Causes an sim11-fold increase in sildenafil AUC; requires a maximum dose restriction of 25 mg in a 48-hour period.
Moderate CYP3A4 Inhibition	Ketoconazole, Erythromycin, Saquinavir	Documented to reduce clearance and increase plasma concentrations.

---

Pharmacodynamic and Other Constraints

• Alpha-blockers: Concomitant use with alpha-blockers (e.g., Doxazosin) may lead to symptomatic hypotension due to additive blood pressure lowering effects. Regulatory documents advise that patients should be hemodynamically stable on alpha-blocker therapy prior to initiating sildenafil.
• Food: Intake with a high-fat meal officially results in a reduced rate of absorption ( T max is delayed) and a reduced peak plasma concentration ( C max).
• Population Notes: Sildenafil clearance is reduced in patients with severe renal impairment and hepatic impairment (e.g., cirrhosis), which can increase interaction relevance.

The active substance is a phosphodiesterase type 5 (PDE5) inhibitor. Its mechanism of action centers on modulating the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway, resulting in relaxation of vascular smooth muscle and alteration of localized hemodynamic properties.

---

Enzyme-Mediated Signaling Modulation

The drug exerts its primary action by selectively inhibiting the PDE5 enzyme. This mechanistic domain involves blocking the enzyme responsible for the degradation of cGMP, a key second messenger in certain signaling pathways. By engaging this mechanism, the drug sustains higher levels of cGMP, thereby decreasing the rate of cGMP hydrolysis.

---

Vasodilation Signaling Cascade

The elevation of cGMP levels initiates a downstream mechanistic cascade within vascular smooth muscle cells. This cascade facilitates reduced contractility in vascular smooth muscle cells, leading to vascular lumen expansion. This consequence involves a localized shift in hemodynamic balance, which is a downstream effect of the inhibited enzyme activity.

Degra (sildenafil) is administered via two approved routes: oral intake (as a film-coated tablet or suspension) and intravenous (IV) injection, which is reserved for the pulmonary arterial hypertension (PAH) indication when a patient cannot take the medicine by mouth. The official dosing regimen is strictly dependent on the condition being addressed.

For Erectile Dysfunction (ED), the medicine is taken as needed (PRN), with a common starting dose of 50 mg. The dose may be adjusted from 25 mg up to a maximum of 100 mg, and this frequency must not exceed once per day. The tablet may be taken with or without food, though administration alongside a high-fat meal can lead to a delay in drug absorption.

Conversely, for the PAH indication, sildenafil is used as a maintenance therapy, administered on a fixed schedule, typically three times a day (TID). The oral dose for PAH usually begins at 20 mg and can be titrated up to a maximum of 80 mg TID.

Special procedural conditions exist for certain populations. A lower starting dose of 25 mg for the ED indication is officially advised for older adults (65 years and over) and patients with severe hepatic or renal impairment due to expected reductions in drug clearance. Furthermore, the powder for oral suspension requires specific reconstitution with water and use of a calibrated measuring device.

Research evidence / Overview of studies for Degra

Evidence for use in Erectile Dysfunction (ED)

Sildenafil was evaluated in research contexts involving fluctuating or unstable symptoms such as erectile dysfunction, with evidence primarily derived from short-term randomized controlled trials (RCTs). These studies were applied in research exploring how symptoms change over time and how they compare to an inactive substance (placebo). The research was generally conducted on adult males, and studies monitored cohorts with co-existing conditions, such as outcomes related to systemic or functional imbalance associated with diabetes or high blood pressure. These studies monitored patient-reported outcomes describing perceived discomfort and assessed outcomes reflecting daily functioning or activity level using specialized scales.

Findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort and the ability to attain and maintain an erection. The evidence gathered contributes to the broader evidence landscape by helping to contextualize how patients reported their experience during these short-term trials. It is important to note that follow-up durations were limited in many primary efficacy studies. This means that long-term effects are not fully established regarding how the reported findings might endure over many years of use.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research exploring Sildenafil for Pulmonary Arterial Hypertension (PAH) was conducted using both short-term RCTs and subsequent long-term extension studies. Studies monitored outcomes related to daily functioning or activity level, such as the six-minute walk distance (6MWD). Initial core trials typically lasted between 12 and 16 weeks. Long-term follow-up was generally observed in studies designed to assess continued use rather than evaluating long-term changes over a multi-year period in a blinded setting.

What Remains Uncertain: Documented Research Gaps

The available evidence highlights areas where more research is needed or where certainty remains low. Comparative evidence is lacking for direct, head-to-head trials against all similar therapeutic options for both ED and PAH. Furthermore, a significant gap exists regarding the use of this medicine in the pediatric PAH population, where subgroup findings are uncertain, and research is still ongoing regarding long-term outcomes across different dose levels.

Key Studies & References

1. Sildenafil Citrate in the Treatment of Erectile Dysfunction: A Dose-Response Study
2. Sildenafil for the treatment of pulmonary hypertension in children: a randomized, double-blind, placebo-controlled, dose-ranging study (STARTS-1)
3. Sildenafil in the treatment of pulmonary arterial hypertension in children: the STARTS-2 study
4. Erectile dysfunction: management and assessment: NICE Guideline

Common questions about Degra (FAQ)

Q: How quickly does Degra start working?

According to clinical trial data, the onset of action for the as-needed use of Degra is reported to occur within 30 minutes after taking the medicine. Individual experience with the onset of effect may vary.

Q: How long do the effects of Degra last?

The duration of the medicine's primary effect for the as-needed indication is generally considered to last up to 4 hours after a dose is administered. This is consistent with the dosage guidelines documented in the official prescribing information for that use.

Q: Is it normal to feel dizzy after starting Degra?

Dizziness is listed in the regulatory safety profile as a common side effect. The common classification indicates that this effect is documented in a fraction of people taking the medicine (1 in 100 to 1 in 10).

Q: How does the time of day affect when I should take Degra?

The timing depends on the medical condition being addressed. For the treatment of PAH, the medicine is taken on a fixed, scheduled basis, typically three times a day (TID). For the as-needed use, official documents note that taking the tablet with a high-fat meal may delay its absorption.

Q: Can I break the Degra tablet in half?

Official prescribing information describes the ED medicine as a film-coated tablet. The product labeling does not contain specific instructions for splitting or crushing these tablets. The medicine should be used exactly as described in the official instructions.

Q: Are there generic versions of Degra available?

Yes, the active ingredient in Degra, which is sildenafil, is available in generic versions. These generics have received regulatory approval for the same indications as the brand-name medicine.

Q: Is Degra the same type of medicine as [similar drug name]?

Degra contains sildenafil, which is classified as a Phosphodiesterase type 5 (PDE5) inhibitor. Drugs in this pharmacological class share the same general mechanism, which involves influencing the body's nitric oxide/cGMP pathway to promote smooth muscle relaxation and increase blood flow.

Q: What should I do if I miss a scheduled dose of Degra?

Official prescribing information for the PAH indication defines the appropriate procedure for a missed scheduled dose, which may vary depending on the proximity of the next dose. Details are provided in the official documentation.

Q: Why do some people use Degra for conditions other than its main purpose?

Degra is officially approved and regulated by health authorities only for the management of Erectile Dysfunction (ED) and for the treatment of Pulmonary Arterial Hypertension (PAH). Regulatory documents define the intended use only for these specific conditions.

Q: Does Degra cause weight gain or loss?

Clinical safety data from studies for the PAH indication lists increased weight and fluid retention as common metabolic side effects that have been documented.

Q: Can Degra cause problems with sleep?

Regulatory safety information lists insomnia (difficulty sleeping) as a common side effect of the medicine. This effect is noted within the classification of documented side effects.

Q: Is it true that Degra has a high interaction risk with heart medications?

The medicine is contraindicated (formally prohibited) for use with all forms of organic nitrates or nitric oxide donors. This combination carries a specific and severe risk of a potentially life-threatening drop in blood pressure.

Q: Is Degra only for men, or can women take it too?

While use for Erectile Dysfunction (ED) is studied in adult males, the active ingredient in Degra, sildenafil, is approved by regulatory authorities for the treatment of Pulmonary Arterial Hypertension (PAH) in both men and women.

Q: Does taking Degra make my skin more sensitive to the sun?

Safety data includes reports of a photosensitivity reaction as a documented dermatologic adverse event. This involves an increased sensitivity or reaction to sunlight.

Q: Are allergic reactions to Degra common?

Hypersensitivity (allergic reactions) is documented as an uncommon side effect, meaning it is reported to occur in less than 1 in 100 people. Serious allergic reactions are considered rare.

Q: How is the research on Degra different from its competitors?

Official regulatory documents note that a lack of comparative evidence exists for direct, head-to-head trials against all similar therapeutic options for the approved conditions. The official research overview highlights a need for direct, head-to-head trials against similar therapeutic options for the approved conditions.

Q: What are the signs of a serious side effect from Degra that require immediate attention?

Serious effects documented in regulatory labeling include a prolonged erection lasting longer than four hours (priapism), sudden vision loss, sudden decrease or loss of hearing, and episodes of chest pain have also been documented in association with use.

Q: Does Degra interact with herbal remedies like St. John's Wort?

Official safety information notes that St. John's wort, a common herbal supplement, may reduce the blood levels and overall effects of the active ingredient in Degra. This is due to its influence on the drug's metabolism.

Q: Is Degra known to interact with grapefruit juice?

Official documentation advises against or recommends limiting consumption of grapefruit and grapefruit juice, as they can potentially increase the concentration of the medicine in the body and delay its absorption.

Q: Can I take Degra if I'm already taking medicine for depression?

Official interaction documents do not list common antidepressants as a specific pharmacokinetic interaction risk. However, the medicine's use has been evaluated in clinical studies involving patients who are also managing depression.

Q: Does Degra affect liver function?

The medicine is primarily metabolized by the liver, and its use is contraindicated in patients with severe hepatic impairment. Reports of drug-related liver toxicity are documented as a very rare post-marketing event.

How to Store and Dispose of Degarelix (Degra)

The storage and disposal requirements for degarelix are defined by official regulatory standards to maintain product stability and ensure safe disposal.

Storage Conditions

Product State	Temperature and Protection
Unreconstituted Powder & Solvent	Store below 25 C (or at room temperature) and keep in the original packaging, protected from light.
Reconstituted Solution	Must be used immediately to ensure microbiological quality. Chemical and physical stability is demonstrated for up to 2 hours at 25 C.

Handling and Disposal

Keep the medicine out of the sight and reach of children. Do not use the product after the expiration date printed on the packaging. When preparing the solution, swirl gently and avoid shaking the vial. The product must not be mixed with other medicines. Used needles, syringes, and any unused or expired medicine must be disposed of in a designated sharps container and according to local requirements; do not dispose of them in household trash or down the sink.